Reuters Events, in partnership with Prognos Health, surveyed 215 brand, marketing, commercial strategy, medical affairs, and data science professionals in the pharmaceutical industry to understand current challenges and opportunities with real-world data (RWD) for therapy commercialization.
Leverage the clinical and diagnostic value of lab data to predict the future cost of healthcare more accurately than manual rate and prescription claims data alone with the PrognosⓇ Underwriting Risk Prediction tool.
Analyzing de-identified patient data is essential to optimize commercial brand strategy. But current methods of obtaining this data can be challenging. See how you can accelerate your path to clinical truth with interoperable patient data and analytics software.
Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.